<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="DrugBank ID: db13609 DrugCentral: umifenovir Synonymous :umifenovir 
Drug Sentece Context Table 1. Analysis of context sentence of umifenovir gene in 58 abstracts.   pmid  sentence      32297571  Inaddition, remdesivir, which has been previously administered to Ebola virus patients, has alsoproven effective in the U.">

  
  <link rel="alternate" hreflang="en-us" href="https://platcovid.com/drugpanel/umifenovir/info/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-166873339-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-166873339-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://platcovid.com/drugpanel/umifenovir/info/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="PlatCOVID">
  <meta property="og:url" content="https://platcovid.com/drugpanel/umifenovir/info/">
  <meta property="og:title" content="UMIFENOVIR | PlatCOVID">
  <meta property="og:description" content="DrugBank ID: db13609 DrugCentral: umifenovir Synonymous :umifenovir 
Drug Sentece Context Table 1. Analysis of context sentence of umifenovir gene in 58 abstracts.   pmid  sentence      32297571  Inaddition, remdesivir, which has been previously administered to Ebola virus patients, has alsoproven effective in the U."><meta property="og:image" content="https://platcovid.com/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="https://platcovid.com/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2019-05-05T00:00:00&#43;01:00">
    
    <meta property="article:modified_time" content="2019-05-05T00:00:00&#43;01:00">
  

  



  


  


  





  <title>UMIFENOVIR | PlatCOVID</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link  active" href="/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  <article class="article">

  












  

  
  
  
<div class="article-container pt-3">
  <p style="font-size:25px" align="justify">UMIFENOVIR</p>

  

  
    


<div class="article-metadata">

  
  

  

  

  

  
  
  

  
  

</div>

    














  
</div>



  <div class="article-container">

    <div class="article-style">
      
<script src="/rmarkdown-libs/kePrint/kePrint.js"></script>
<link href="/rmarkdown-libs/lightable/lightable.css" rel="stylesheet" />


<hr />
<p align="left" style="font-size:16px">
DrugBank ID: <a href='https://www.drugbank.ca/drugs/db13609' target='_blank'>db13609</a> <br>
DrugCentral: <a href="http://drugcentral.org/?q=umifenovir" target="_blank">umifenovir</a> <br>
Synonymous :umifenovir
</p>
<p><br></p>
<hr />
<div id="drug-sentece-context" class="section level2">
<h2>Drug Sentece Context</h2>
<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> Analysis of context sentence of <em>umifenovir</em> gene in 58 abstracts.
</p>
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
pmid
</th>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
sentence
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
<a href="/publication/32297571" target="_blank">32297571</a>
</td>
<td style="text-align:center;">
Inaddition, remdesivir, which has been previously administered to Ebola virus patients, has alsoproven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxy-chloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies)were also recently recorded as having anti-SARS-CoV-2 effects.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32324898" target="_blank">32324898</a>
</td>
<td style="text-align:center;">
The ADR could be explained by the use of lopinavir/ ritonavir and umifenovir by 63.8% and 18.1%, respectively.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32344167" target="_blank">32344167</a>
</td>
<td style="text-align:center;">
Umifenovir (Arbidol®) is an antiviral drug being used to treat influenza in Russia and China. […] This study aimed to investigate the effectiveness and safety of umifenovir for COVID-19. […] The confirmed patients were divided into the umifenovir group and the control group according to the use of umifenovir. […] A total of 81 COVID-19 patients were included, with 45 in the umifenovir group and 36 in the control group. […] Thirty-three out of 45 (73%) patients in the umifenovir group tested negative for SARS-CoV-2 within 7 days after admission, the number was 28/36 (78%) in the control group (p 0.19). […] The median time from onset of symptoms to SARS-CoV-2 turning negative was 18 days (interquartile range (IQR) 12-21) in the umifenovir group and 16 days (IQR 11-21) in the control group (p 0.42). […] Patients in the umifenovir group had a longer hospital stay than patients in the control group (13 days (IQR 9-17) vs 11 days (IQR 9-14), p 0.04). […] Umifenovir might not improve the prognosis or accelerate SARS-CoV-2 clearance in non-ICU patients. […] A randomized control clinical trial is needed to assess the efficacy of umifenovir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32360231" target="_blank">32360231</a>
</td>
<td style="text-align:center;">
This article reports the potential drug target and mechanism of action of Arbidol (umifenovir) to treat coronavirus disease 2019 (COVID-19).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32393381" target="_blank">32393381</a>
</td>
<td style="text-align:center;">
Arbidol (Umifenovir; an anti-influza drug; 69.2%) was the drug most commonly used to target infection in mild and moderate symptoms.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32395418" target="_blank">32395418</a>
</td>
<td style="text-align:center;">
These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32405421" target="_blank">32405421</a>
</td>
<td style="text-align:center;">
Comparator drugs were oseltamivir, umifenovir, lopinavir/ritonavir or placebo.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32409433" target="_blank">32409433</a>
</td>
<td style="text-align:center;">
Antivirals to treat influenza (oseltamivir) have limited activity against SARS-CoV-2, but favipiravir and umifenovir, two influenza antivirals available internationally, may have distinct viral targets and require further investigation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32493740" target="_blank">32493740</a>
</td>
<td style="text-align:center;">
We included studies of ribavirin, chloroquine, hydroxychloroquine, umifenovir (arbidol), favipravir, interferon and lopinavir/ritonavir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32514689" target="_blank">32514689</a>
</td>
<td style="text-align:center;">
Additionally, seven pharmacological agents (chloroquine, tetrandrine, umifenovir (arbidol), carrimycin, damageprevir, lopinavir/ritonavir) are in phase IV of clinical trials.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32515383" target="_blank">32515383</a>
</td>
<td style="text-align:center;">
Umifenovir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32532939" target="_blank">32532939</a>
</td>
<td style="text-align:center;">
Hydroxychloroquine, lopinavir/ritonavir, remdesivir, umifenovir, favipiravir, ribavirin and beta-interferon-1 gave rise to variable but still inconsistent proof of clinical efficacy in the treatment of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32565309" target="_blank">32565309</a>
</td>
<td style="text-align:center;">
Our results for the first time suggest that a quadruple combination therapy (Ribavirin, Lopinavir/ritonavir, Umifenovir, and Lianhua Qingwen) can be considered as a preferred treatment approach to severe COVID-19 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32572842" target="_blank">32572842</a>
</td>
<td style="text-align:center;">
In particular, information has spread about some drugs approved for other indications (chloroquine, hydroxychloroquine, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, favipiravir, and umifenovir) that could have led to inappropriate and therefore hazardous use.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32617989" target="_blank">32617989</a>
</td>
<td style="text-align:center;">
We conducted this systemic review and meta-analysis in an attempt to evaluate the efficacy and safety of umifenovir in coronavirus disease 2019 (COVID-19). […] The mean difference (MD) and risk ratio (RR) with 95% confidence intervals (CI) were applied to assess the effectiveness of umifenovir for COVID-19. […] Compared with control group, umifenovir was associated with higher negative rate of PCR on day 14 (RR:1.27; 95% CI: 1.04 to 1.55). […] However, umifenovir is not related to nucleus acid negative conversion time (MD: 0.09; 95% CI: -1.48 to 1.65), negative rate on day 7 (RR:1.09; 95% CI: 0.91 to 1.31), incidence of composite endpoint (RR:1.20; 95% CI: 0.61 to 2.37), rate of fever alleviation on day 7 (RR:1.00; 95% CI: 0.91 to 1.10), rate of cough alleviation on day 7 (RR:1.00; 95% CI: 0.85 to 1.18), or hospital length of stay (MD: 1.34; 95% CI: -2.08 to 4.76). […] Additionally, umifenovir was safe in COVID-19 patients (RR for incidence of adverse events: 1.29; 95% CI: 0.57 to 2.92). […] There is no evidence to support the use of umifenovir for improving patient-important outcomes in patients with COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32634603" target="_blank">32634603</a>
</td>
<td style="text-align:center;">
The antiviral therapies remdesivir, lopinavir/ritonavir and umifenovir, if considered, should be initiated before the peak of viral replication for an optimal outcome.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32679055" target="_blank">32679055</a>
</td>
<td style="text-align:center;">
We report the antiviral effect of remdesivir, lopinavir, chloroquine, umifenovir, berberine and cyclosporine A in Vero E6 cells model of SARS-CoV-2 infection, with estimated 50% inhibitory concentrations of 0.99, 5.2, 1.38, 3.5, 10.6 and 3 μM, respectively.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32685234" target="_blank">32685234</a>
</td>
<td style="text-align:center;">
Currently, the management of patients with COVID-19 depends mainly on repurposed drugs which include chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, remdesivir, favipiravir, umifenovir, interferon-α, interferon-β and others.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32694915" target="_blank">32694915</a>
</td>
<td style="text-align:center;">
Hydroxychloroquine/chloroquine, lopinavir/ritonavir, ribavirin, interferons, umifenovir, remdesivir, and interleukin antagonists, such as tocilizumab, have been recommended as potential treatment options in COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32707096" target="_blank">32707096</a>
</td>
<td style="text-align:center;">
Additionally, early IFN-α2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32707160" target="_blank">32707160</a>
</td>
<td style="text-align:center;">
Thus, the aim of this study was to review and evaluate the literature data on the toxicity of the selected individual drugs (ritonavir, lopinavir, remdesivir, chloroquine, and umifenovir) and the available clinical data concerning the possible adverse effects of the selected drug combinations (lopinavir/ritonavir + umifenovir, lopinavir/ritonavir + interferon β, chloroquine + remdesivir, and chloroquine + azithromycin).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32735768" target="_blank">32735768</a>
</td>
<td style="text-align:center;">
Supportive care and management of the complications that are caused mainly by inflammation might be the key to greater survival rates and shorter hospitalization (e.g., the use of remdesivir, lopinavir, ritonavir, umifenovir (arbidol), oseltamivir, ganciclovir, favipiravir, darunavir, hydroxychloroquine, chloroquine, colchicine, azithromycin, anakinra, canakinumab, tocilizumab, siltuximab, sarilumab, Type 1 interferon, interferon β-1a, interferon α- 2b, baricitinib, ruxolitinib, fedratinib, methylprednisolone and dexamethasone).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32752944" target="_blank">32752944</a>
</td>
<td style="text-align:center;">
Therefore, this review focuses on the current use of various drugs as single agents (hydroxychloroquine, ivermectin, azithromycin, favipiravir, remdesivir, umifenovir, teicoplanin, nitazoxanide, doxycycline, and dexamethasone) or in combinations with immunomodulators additionally.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32754388" target="_blank">32754388</a>
</td>
<td style="text-align:center;">
In this article, we have compiled comprehensive data on many candidate drugs such as remdesivir, favipiravir, ribavirin, umifenovir, arbidol, lopinavir, ritonavir, baricitinib, hydroxychloroquine, nitazoxanide, azithromycin, baloxavir, oseltamivir, losartan, and tocilizumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32754599" target="_blank">32754599</a>
</td>
<td style="text-align:center;">
Nonetheless, the combination of umifenovir and LPV/r was found to have better antiviral activity.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32768505" target="_blank">32768505</a>
</td>
<td style="text-align:center;">
These include anti-viral agents (remdesivir, ribavirin, lopinavir-ritonavir, favipiravir, chloroquine, hydroxychloroquine, oseltamivir, umifenovir), immunomodulatory agents (tocilizumab, interferons, plasma transfusions), and adjunctive agents (azithromycin, corticosteroids), among other miscellaneous agents.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32773212" target="_blank">32773212</a>
</td>
<td style="text-align:center;">
Umifenovir (Arbidol) was associated with reduction in mortality in few studies.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32815796" target="_blank">32815796</a>
</td>
<td style="text-align:center;">
We employed the antitussive noscapine in conjugation with antiviral drugs (Chloroquine, Umifenovir, Hydroxychloroquine, Favlplravir and Galidesivir).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32838264" target="_blank">32838264</a>
</td>
<td style="text-align:center;">
Other candidates including tocilizumab, other interleukin 6 inhibitors, umifenovir, and favipiravir have insufficient data on pregnancy outcomes.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32838713" target="_blank">32838713</a>
</td>
<td style="text-align:center;">
Existing antivirals such as ASC09/ritonavir, lopinavir/ritonavir with or without umifenovir in combination with antimalarial chloroquine or hydroxychloroquine have been repurposed to fight the current coronavirus epidemic.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32848446" target="_blank">32848446</a>
</td>
<td style="text-align:center;">
Antiviral medication (lopinavir, darunavir, favipiravir, remdesivir, ribavirin, oseltamivir, tocilizumab, and umifenovir), ACE inhibitors, interferon-α2b, co-therapy with azithromycin, inhaling iNO, and oxygen therapy can be used for treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32849448" target="_blank">32849448</a>
</td>
<td style="text-align:center;">
These drugs include the broad spectrum antivirals such as umifenovir, protease inhibitors such as lopinavir/ritonavir as well as the RNA-dependent RNA polymerase inhibitors, remdesivir, and favipiravir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32849934" target="_blank">32849934</a>
</td>
<td style="text-align:center;">
We conclude from the evidence generated so far that interferon combined with antivirals, remdesivir, umifenovir and favipiravir were mostly associated with better clinical outcomes.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32850989" target="_blank">32850989</a>
</td>
<td style="text-align:center;">
Pharmacological strategies that interfere with the viral attachment to ACE2 (umifenovir and hydroxychloroquine/chloroquine) or that modulate the RAS (analogous of A1-7 and ACE2, losartan) are in clinical development for COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32887670" target="_blank">32887670</a>
</td>
<td style="text-align:center;">
They covered topics of chemoprophylaxis (including agents and Traditional Chinese Medicine (TCM) agents), diagnosis (including clinical manifestations, reverse transcription-polymerase chain reaction (RT-PCR), respiratory tract specimens, IgM and IgG antibody tests, chest computed tomography, chest x-ray, and CT features of asymptomatic infections), treatments (including lopinavir-ritonavir, umifenovir, favipiravir, interferon, remdesivir, combination of antiviral drugs, hydroxychloroquine/chloroquine, interleukin-6 inhibitors, interleukin-1 inhibitors, glucocorticoid, qingfei paidu decoction, lianhua qingwen granules/capsules, convalescent plasma, lung transplantation, invasive or noninvasive ventilation, and extracorporeal membrane oxygenation (ECMO)), and discharge management (including discharge criteria and management plan in patients whose RT-PCR retesting shows SARS-CoV-2 positive after discharge).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32924650" target="_blank">32924650</a>
</td>
<td style="text-align:center;">
The narrative synthesis revealed three key themes (1) Use of antivirals only (such as lopinavir, umifenovir, and remdesivir), (2) Use of lopinavir-ritonavir alongside other treatments, and (3) Use of other antivirals in combination with other treatments.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32941741" target="_blank">32941741</a>
</td>
<td style="text-align:center;">
To understand the clinical effectiveness and safety of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33008960" target="_blank">33008960</a>
</td>
<td style="text-align:center;">
Therapies focus on blocking viral entry (remdesivir, umifenovir, among others) and blocking of immune system for cytokine storm control (IL-1 and IL-6 inhibitors, glucocorticoids, convalescent plasma, among others).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33029696" target="_blank">33029696</a>
</td>
<td style="text-align:center;">
The repurposed drugs like Chloroquine and Hydroxychloroquine, Tenofovir, Remdesivir, Ribavirin, Darunavir, Oseltamivir, Arbidol (Umifenovir), Favipiravir, Anakinra, and Baricitinib are already being used in clinical trials to treat the COVID-19 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33031797" target="_blank">33031797</a>
</td>
<td style="text-align:center;">
So far, chloroquine, lopinavir, hydroxychloroquine, azithromycin, favipiravir, ribavirin, darunavir, remdesivir, and umifenovir have been tested in COVID-19 clinical trials. […] Conversely, drugs with poor lung distributions, including lopinavir/ritonavir, umifenovir and remdesivir, were insufficient to inhibit viral replication.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33041830" target="_blank">33041830</a>
</td>
<td style="text-align:center;">
These include antivirals (remdesivir, lopinavir/ritonavir, umifenovir, and favipiravir), interferon, antimalarials (chloroquine/hydroxychloroquine), antiparasitic drugs (ivermectin and nitazoxanide), biologics (monoclonal antibodies and interleukin receptor antagonist), cellular therapies (mesenchymal stem cells and natural killer cells), convalescent plasma, and cytokine adsorber.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33102687" target="_blank">33102687</a>
</td>
<td style="text-align:center;">
The results indicate promising effects of such compounds to be used in further experimental and clinical trials; Chloroquine, Chloroquine-OH, and Umifenovir as viral entry inhibitors, Remdesivir, Ribavirin, Lopinavir, Ritonavir, and Darunavir as viral replication inhibitors, and Sirolimus are the examples, which were tested clinically on patients after comprehensive assessments of the available data on molecular simulation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33130203" target="_blank">33130203</a>
</td>
<td style="text-align:center;">
From the clinical studies in COVID-19, it has shown rapid viral clearance as compared to lopinavir/ritonavir (LPV/RTV) and superior recovery rate than umifenovir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33154404" target="_blank">33154404</a>
</td>
<td style="text-align:center;">
Moreover, Baricitinib and Umifenovir were found to have superior target-specific binding while Darunavir is found to be a potential multi-targeting drug.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33156564" target="_blank">33156564</a>
</td>
<td style="text-align:center;">
The list of drugs used for COVID-19 treatment includes a combination of lopinavir and ritonavir, remdesivir, favipiravir, alpha-interferon, ribavirin, atazanavir, umifenovir, and tocilizumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33194192" target="_blank">33194192</a>
</td>
<td style="text-align:center;">
Umifenovir, and low and short courses of glucocorticoids were not associated with prolonged viral shedding.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33257051" target="_blank">33257051</a>
</td>
<td style="text-align:center;">
Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33290969" target="_blank">33290969</a>
</td>
<td style="text-align:center;">
Antiviral drugs such as; oseltamivir, favipiravir, umifenovir, lopinavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ascorbic acid, corticosteroids, are mostly used for patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33306333" target="_blank">33306333</a>
</td>
<td style="text-align:center;">
Numerous drugs including lopinavir/ritonavir, favipiravir, neuraminidase inhibitors, remdesivir, umifenovir, azithromycin and chloroquine have been suggested for the management of COVID-19 although the exact treatment yet to be determined.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33333292" target="_blank">33333292</a>
</td>
<td style="text-align:center;">
Sixteen synergistic and eight antagonistic combinations were identified; among 16 synergistic cases, combinations of the US Food and Drug Administration (FDA)-approved drug nitazoxanide with remdesivir, amodiaquine, or umifenovir were most notable, all exhibiting significant synergy against SARS-CoV-2 in a cell model.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33334287" target="_blank">33334287</a>
</td>
<td style="text-align:center;">
The development of vaccine or medicines for the same are under progress and this short review will summarize the most potential candidates such as Remdesivir, Lopinavir and Ritonavir, Chloroquine, Hydroxychloroquine, Hydroxychloroquine with Azithromycin, Favipiravir, Umifenovir, and Ribavirin for its medicinal treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33336780" target="_blank">33336780</a>
</td>
<td style="text-align:center;">
Umifenovir, remdesivir, and fevipiravir are deemed the most hopeful antiviral agent by improving the health of infected patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33341481" target="_blank">33341481</a>
</td>
<td style="text-align:center;">
Currently, some researchers and clinicians have claimed evidence exists in favor of the use of some antimalarial drugs (chloroquine, hydroxychloroquine) antiviral drugs (remdesivir, favipiravir, lopinavir, ritonavir, umifenovir) vitamins, traditional Chinese medicines, and herbal medicines against SARS-CoV-2 infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33342420" target="_blank">33342420</a>
</td>
<td style="text-align:center;">
Several drugs such as Hydroxychloroquine, Umifenovir, Remdesivir, Lopinavir/Ritonavir, interferon, Darunavir, Favipiravir, Nitazoxanide etc. are currently undergoing clinical studies to test the safety and efficacy of the drug against this pandemic.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33458647" target="_blank">33458647</a>
</td>
<td style="text-align:center;">
Many promising antiviral agents including lopinavir, ritonavir, remdesivir, umifenovir, darunavir, and oseltamivir have been repurposed and are currently trialled in the care for COVID-19 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33466134" target="_blank">33466134</a>
</td>
<td style="text-align:center;">
Fifty-three patients (96.36%) received antiviral therapy, including 45 in the mild group (median treatment: 14 days; 17 received umifenovir) and all 8 severe-group patients (median treatment: 17.5 days; 4 received lopinavir/ritonavir). […] Umifenovir may benefit patients with mild symptoms, while lopinavir/ritonavir may benefit those with severe symptoms.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33533219" target="_blank">33533219</a>
</td>
<td style="text-align:center;">
The review discusses the main representatives of these groups of drugs - ribavirin, riamilovir, umifenovir, favipiravir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33538665" target="_blank">33538665</a>
</td>
<td style="text-align:center;">
This paper is prepared to reveal about an urgent industrial scheme for a fast and facile total synthesis of umifenovir (arbidol) (by one-pot stages) as an antiviral agent for treating 2019-nCoV virus via inhibiting its viral replication in the human cells.
</td>
</tr>
</tbody>
</table>
</div>

    </div>

    





















  </div>
</article>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.4aaf2d64e50f8e54cf66dcc54147a22e.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      
      <a href="/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
